drugset / Trial / NCT02595736

A Study of LY3200327 in Healthy Participants

NCT02595736 ↗

Phase 1 Completed 52 enrolled Eli Lilly and Company
RandomizedParallel-groupDouble-blindBasic science

Summary

The purpose of this study is to look at the safety and tolerability of single doses of LY3200327 when given to healthy male and female participants either by injection under the skin or by drip into a vein. The study will help determine how the drug behaves inside the body and how long it takes to disappear from the body. The study will also look for anti-drug antibodies and how these may affect how LY3200327 acts in your body. The study is expected to last approximately 12 weeks (with screening evaluations up to 4 weeks prior).

Timeline

Start
2015-11
Primary completion
2016-08
Completion
2016-08

Drugs

EvaluationDrugModalityDoseRoute
Subject LY3200327 Unknown — Subcutaneous

Indications

No indication recorded.